StockHideout.com sent out an Alert on NFRM this morning:

National Pharmaceuticals Corp. (NFRM) is a 9-month old biotech company on the verge of commercializing its flagship chronic pain treatments.
 
And to help push NFRM’s product development even faster towards commercialization…
 
On March 3, NFRM announced it had reached an exclusive partnership agreement with Globe Laboratories – which will develop NFRM’s new anti-inflammatory line of drugs. (Read more)
 
NFRM CEO Elaine Affleck said, regarding Globe: “…This highly qualified team can shorten the time needed to bring our drugs to the market successfully. Overall, having contracted out the work to this team of experts, should guarantee NFRM a higher rate of success for its drugs.”
 
And ever since NFRM announced the partnership, its stock has posted steady volume days – with as much as 1.4 million shares traded – which, in turn, have sparked huge gains in the stock – as high as 190%!
 
Since then, and predictably, it’s consolidated, but right now I like how the chart is shaping up…
 
NFRM has already tested and closed above support twice. Better still, volume was over 500K on the retest.
 
You’ve seen this pattern before, my friend…so let me put it simply: The bottom was just bought!
 
 
NFRM Trend Highlights
 
Trading has been steady and heavy, with some intraday volume crossing over one million shares.
 
The trading range has been wide and volatile, with the low at .10 and highs up to .35, a swing of 250%.
 
On an intraday basis, NFRM has shown strength and deep interest, with sessions seeing effortless swings between 40% and 94%!

NFRM Technical Highlights
 
A recent test of the .10 low showcased NFRM’s strength – the stock closed at the .14 high, a swing of 40%!
 
The next session’s retest of the consolidation low brought significant volume of 500K and a close at the 50-day MA!